BIO, Al­ler­gan and Roche call for FDA flex­i­bil­i­ty with pa­tient ex­pe­ri­ence da­ta

In­dus­try group BIO and bio­phar­ma com­pa­nies Al­ler­gan and Roche are call­ing for the FDA to be flex­i­ble in its ap­proach for us­ing pa­tient ex­pe­ri­ence da­ta (PED) and in al­low­ing the use of such da­ta in la­bel­ing.

BIO said that it “strong­ly be­lieves” that in or­der for a broad adop­tion of PED, any up­com­ing guid­ance doc­u­ments on pa­tient-fo­cused drug de­vel­op­ment “should em­pha­size the FDA’s will­ing­ness to ex­er­cise reg­u­la­to­ry flex­i­bil­i­ty and ac­cep­tance of in­no­v­a­tive de­signs and ap­proach­es for col­lect­ing PED.”

Danielle Friend

For ex­am­ple, the draft guid­ance on gath­er­ing pa­tient in­put, ac­cord­ing to Danielle Friend, di­rec­tor of sci­ence and reg­u­la­to­ry af­fairs at BIO, is “high­ly fo­cused on sta­tis­ti­cal re­quire­ments for col­lec­tion of sub­jec­tive mea­sures and al­though rep­re­sen­ta­tion of the pop­u­la­tion is para­mount, there is al­so a need to bal­ance such rep­re­sen­ta­tive­ness with sta­tis­ti­cal va­lid­i­ty, as the re­quire­ment of many stra­ta for rep­re­sen­ta­tion could have a neg­a­tive im­pact on sta­tis­ti­cal pow­er.”

Sim­i­lar to BIO, Al­ler­gan urges the FDA to con­sid­er the need for flex­i­bil­i­ty with re­spect to the method­olog­i­cal re­quire­ments and op­por­tu­ni­ties for en­gage­ment to pro­vide spon­sors with clar­i­ty to in­form ev­i­dence gen­er­a­tion in a time­ly man­ner.

BIO al­so calls for flex­i­bil­i­ty on sam­pling meth­ods and in col­lect­ing da­ta for small­er pa­tient pop­u­la­tions, such as with rare dis­eases. The in­dus­try group ad­di­tion­al­ly re­quests that the FDA de­lin­eate be­tween col­lect­ing PED to in­form clin­i­cal stud­ies (e.g., de­vel­op­ment of a clin­i­cal out­come as­sess­ment tool or to in­form clin­i­cal study end­points) and PED col­lect­ed with­in a clin­i­cal study meant to in­form a reg­u­la­to­ry de­ci­sion.

Roche’s Genen­tech, mean­while, calls on the agency to fur­ther clar­i­fy when PED can be la­bel-en­abling.

Janet Jenk­ins-Showal­ter

“As dif­fer­ent types of pa­tient ex­pe­ri­ence da­ta serve dif­fer­ent pur­pos­es, we urge the FDA to de­scribe rea­son­able stan­dards that en­able the in­clu­sion of fit-for-pur­pose pa­tient ex­pe­ri­ence da­ta with­in dif­fer­ent sec­tions of drug la­bel,” Janet Jenk­ins-Showal­ter, head of US reg­u­la­to­ry pol­i­cy at Genen­tech, writes.

Al­ler­gan al­so calls on the FDA to sub­stan­ti­ate the dif­fer­ences in ev­i­den­tiary stan­dards for PED for reg­u­la­to­ry-de­ci­sion mak­ing vs. la­bel­ing.

Jenk­ins-Showal­ter adds: “We would al­so high­light the im­por­tance of cre­den­tial­ing and shar­ing pa­tient ex­pe­ri­ence da­ta deemed of suf­fi­cient qual­i­ty to in­form drug de­vel­op­ment pro­gram de­sign (e.g., bur­den of dis­ease, bur­den of ex­ist­ing treat­ments) that is col­lect­ed out­side the con­text of an IND pro­gram. It is im­por­tant that these reg­u­la­to­ry qual­i­ty da­ta are shared with the broad­er com­mu­ni­ty of Spon­sors, mea­sure­ment sci­en­tists, pa­tients, and reg­u­la­tors such that clin­i­cal sci­ence is able to ad­vance to­wards the de­vel­op­ment of out­comes that are mean­ing­ful to pa­tients.”


First pub­lished here. Reg­u­la­to­ry Fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email news@raps.org for more in­for­ma­tion.

Author

Zachary Brennan

managing editor, RAPS

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

Novartis CEO Vas Narasimhan [via Bloomberg/Getty]

I’m not per­fect: No­var­tis chief Vas Narasimhan al­most apol­o­gizes in the wake of a new cri­sis

Vas Narasimhan has warily stepped up with what might pass as something close to a borderline apology for the latest scandal to engulf Novartis.

But he couldn’t quite get there.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

FDA to Sarep­ta: Your wide­ly an­tic­i­pat­ed fol­lowup to Ex­ondys 51 is not get­ting an ac­cel­er­at­ed OK for Duchenne MD

In one of the least anticipated moves of the year, the FDA has rejected Sarepta’s application for an accelerated approval of its Duchenne MD drug golodirsen after fretting over safety issues.

In a statement that arrived after the bell on Monday, Sarepta explained the CRL, saying:

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

Levi Garraway. Broad Institute via Youtube

Roche raids Eli Lil­ly for its next chief med­ical of­fi­cer as San­dra Horn­ing plans to step down

We found out Monday morning where Levi Garraway was headed after he left Eli Lilly as head of oncology R&D a few days ago. Roche named Garraway as their new chief medical officer, replacing Sandra Horning, who they say is retiring from the company.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA de­ci­sion

As Bloomberg notes, most of the Wall Street analysts that cover Sarepta $SRPT are an upbeat bunch, ready to cheer on the team when it comes to their Duchenne MD drugs, or offer explanations when an odd setback occurs — as happened recently with a safety signal that was ‘erroneously’ reported last week.

Ritu Baral Cowen
Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: No­var­tis spin­off Nabri­va fi­nal­ly scores its first an­tibi­ot­ic ap­proval

In May, Nabriva Therapeutics suffered a setback after the FDA rejected its antibiotic for complicated urinary tract infections — the Novartis spinoff has now had some better luck with the US agency, which on Monday approved its other drug for community-acquired bacterial pneumonia.

The drug, lefamulin, has been developed as an intravenous and oral formulation and been tested in two late-stage clinical trials. The semi-synthetic compound, whose dosing can be switched between the two formulations, is engineered to inhibit the synthesis of bacterial protein by binding to a part of the bacterial ribosome.

Saqib Islam. CheckRare via YouTube

Spring­Works seeks $115M to push Pfiz­er drugs across fin­ish line while Sat­suma sells mi­graine play in $86M IPO

SpringWorks and Satsuma — both biotech spinouts that have closed B rounds in April — are loading up with IPO cash to boost their respective late-stage plans.
SpringWorks

Bain-backed SpringWorks is the better-known company of the two, and it’s gunning for a larger windfall of $115 million to add to $228 million from previous financings. In the process, the Stamford, CT-based team is also drawing the curtains on the partnerships it has in mind for the pair of assets it had initially licensed from Pfizer.

Mi­nor­i­ty racial groups con­tin­ue to be dis­mal­ly rep­re­sent­ed in can­cer tri­als — study

Data reveal that different racial and ethnic groups — by nature and/or nurture — can respond differently in terms of pharmacokinetics, efficacy, or safety to therapeutics, but this disparity is not necessarily accounted for in clinical trials. A fresh analysis of the last decade of US cancer drug approvals suggests the trend continues, cementing previous research that suggests oncology trials are woefully under-representative of the racial makeup of the real world.

Van­da shares slide af­ter FDA spurns their big end­point and re­jects a pitch on jet lag re­lief

Back in the spring of last year, Vanda Pharmaceuticals $VNDA served up a hot stew of mixed data for a slate of endpoints related to what they called clear evidence that their melatonin sleep drug Hetlioz (tasimelteon) could help millions of travelers suffering from jet lag.

Never mind that they couldn’t get a planned 90 people in the study, settling for 25 instead; Vanda CEO Mihael H. Polymeropoulos said they were building on a body of data to prove it would help jet-lagged patients looking for added sleep benefits. And that, they added, would be worth a major upgrade from the agency as they sought to tackle a big market.